ThermoGenesis Holdings, Inc. · OTC:THMO

ThermoGenesis — Q3 2019 Earnings Presentation

26 slides from ThermoGenesis's earnings presentation, Nov 20, 2019

  1. Slide 1: Corporate Strategy Update Accompanying 2019Q3 Earning Call

    Cesca Therapeutics Inc. (NASDAQ:KOO1L) is now ThermoGenesis Holdings, Inc. (NASDAQ:THMO) “A solution provider for automated cell processing tools and services in the cell & gene therapy field” Corporate Strategy Update Accompanying 2019Q3’s Earning Call Updated: November 20, 2019 e 1) Nosdag:THMo Th

  2. Slide 2: Disclosure and Forward Looking Statement

    2]| Disclosure and Forward Looking Statement This presentation includes statements of future expectations and other forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's curren

  3. Slide 3: ThermoGenesis — Company Overview

    ew PhermoGenesis — Company Overview —A leading automated cell processing tool and service provider for the cell and gene therapy field + COMPANY HISTORY: Founded in 1986, the Company is headquartered in Sacramento, CA with™60 FTE. + NEW COMPANY IDENTITY: Previous knowns Cesca Therapeutics, Inc. (Nas

  4. Slide 4: ThermoGenesis ("TG") — Mission

    4] ThermoGenesis (“TG”) — Mission —A leading automated cell processingtool and service providerfor the cell and gene therapy field MISSION Ensure the future benefit of cell and gene therapy to everyone in need through reduction of drug manufacturing cost and increased patient accessibility. 4 | Nasd

  5. Slide 5: Aggressive Revenue Growth & Cost Reduction Strategy

    Gu Aggressive Revenue Growth & Cost Reduction Strategy — Two years of progressive transformation with the company'to achieve profitability Red: revenue growth measures Past 10 (2) Yea Green: cost reduction measures Launched CAR-Txpress Completed ‘completes in-house | [Launchedennanced] {Formed immun

  6. Slide 6: Stronger Financial Performance

    6 | Stronger Financial Performance — Steady improvement in financial results since 2018 Revenue (5 inmiins s50 $43 gat $3.4 $4.0 $3.0 or 30 $2.0 i 9 i y $1.0 $0.0 I Ll 21803 01a 2A 02 1903 Operating Expenses (5 inmilions~exclusngimpsirmers cares) sao $3.6 $3.7 2.8 » | li sees li $2.2 $22 wiser 2102

  7. Slide 7: Adjusted EBITDA Steadily Increased, Reaching Positive

    Adjusted EBITDA Steadily Increased, Reaching Positive — Result of combined measures to increase revenue and reduce costs Adjusted EBITDA by Quarter * Key metric used by the Companyto determine aos c= 2019.03 cash-based results $05 + Adjusted EBITDA is a non-GAAP financial measure*and is defined as e

  8. Slide 8: Our Automated Cell Processing Product Line

    38 | Our Automated Cell Processing Product Line — From stem cell banking, to point-of-care clinical applications, to large scale cellular processing 1. AXP’ Platform for Stem Cell Banking 2.PXP Platform for Point-of-Care Clinical Application 3. CAR-TXpress” Platform for Large Scale Cell Manufacturin

  9. Slide 9: AXP: Leading Automated Technology for Cord Blood Banks

    9 | AXP®: Leading Automated Technology for Cord Blood Banks — Fully automated system for the isolation of stem cells from cord blood with superior performance BioArchive® | NYBC National Cord Blood Program | x AXP Processing Results: N=34,011 CBUs | i eran et a SE) ratsece)|vetpncnce|(omenang || 7 s

  10. Slide 10: Our Future: Enabling Next-Generation Cell Therapies

    Our Future: Enabling Next-Generation Cell Therapies — Cell & gene therapies are advancing rapidly around the world, especially for CAR-T cell therapies Worldwide Trials + 800+CClinical Tals + 900+ Companies Global Market + Global regenerative medicine ‘and cel therapy marketo grow to USS 67.6 Billio

  11. Slide 11: TG Addresses Critical Needs for Lowering CAR-T Drug Cost

    ium | |G Addresses Critical Needs for Lowing CAR-T Drug Cost — Current CAR-T manufacturing process is labor-intensive, time consuming and extremely costly. rr I Scaling up production (33%) | Reimbursement process (25%) [Bi Lengthy development timelines (33%) J Other (9%) CAR-T Manufacture Cost Curre

  12. Slide 12: Our CAR-TXpress Proprietary Cell Processing Platform

    Our CAR-TXpress™ Proprietary Cell Processing Platform —CAR-TXpress is modular designed, semi-automated, closed system for large-scale, high-efficiency cell manufacturing, potentially could reduce 2/3 of the manufacturing cost of CAR-T therapeutics. Proprietary CAR-TXpress™ Platform with Patented X-B

  13. Slide 13: Our Patent Protected BACS Technology

    sey f Our Patent Protected BACS Technology — Proprietary, new approach for separating cells from blood using a “bubbles” Targerceiis | | Non-Targetcetts What It Is: w/ beads w/obeads + BACS uses microscopic bubbles (each smaller than a single cell) as coll isolation reagents. + The microbubbles are

  14. Slide 14: X-Series Products from CAR-TXpress Platform

    iva |) X-Series® Products from CAR-TXpress™ Platform — Highly efficient cell processing, washing and formulation of various cell and gene therapy products X-LAB Harvests & purifies MNCs from blood, bone marrow or leuka- pheresis, depleting up to: 9996 of RBCs, 70% of GRNs, 85% of PLTs, and excess pl

  15. Slide 15: Global Distribution Agreement for X-Series Products

    Global Distribution Agreement for X-Series Products — Partnership with CLS to distribute X-Series products worldwide Key Terms for Global Distribution Agreement: * Fortune 500 company with global sales force + $2M upfront license fee (Received) * Covers entire X-Series product line * Worldwide exclu

  16. Slide 16: ThermoGenesis' Future Growth Strategy

    ThermoGenesis’ Future Growth Strategy — Transforming from a medical device company to a leading solution provider for cell & gene therapies 2019 2020 2024 2022 2023 2024 416 | Nasdaq:THMO ThermoGenesis”

  17. Slide 17: ThermoGenesis Establishes TG-HealthBanks Joint Venture

    17 ThermoGenesis Establishes TG-HealthBanks Joint Venture —ImmuneCyte is among the first U.S. cell banks that provide GMP quality immune cell banking services to healthy individuals as fee-for-services ImmuneCyteis among the first cell banks in the U.S. to provide clients with the opportunity to ban

  18. Slide 18: We Address Critical Unmet Needs in Patient Accessibility

    WeAddress Critical Unmet Needs in Patient Accessibility —ImmuneCyte stores someone's healthy immune cells now for his/her future use, therefore, to improve the opportunities of accessing future CAR-T immunotherapies when needed. Immunotherapy, such as CAR-T cell, has become one of the most promising

  19. Slide 19: ImmuneCyte's Easy Banking Procedures

    ImmuneCyte’s Easy Banking Procedures — Preserving someone's healthy and unaffected immune cells with easy steps, under GMP compliance mpm eanrang 200mI blood Automates CAR-TKpress Plaform, monfonce sesfreaet pippedto Cosed system, GMP compliant immanecytes Fos/aaes - 6 & a Celpuaton nen needed mmuno

  20. Slide 20: CAR-TXpress Platform's Competitive Advantages

    Ya | CAR-TXpress Platform’s Competitive Advantages — Automated, fast, high throughput, GMP compliant, separates multi-ccomponents simultaneously Competitive | CAR-TXpress™ Ficoll® Advantage System Reagent P Fropielay Genene vines Aomated Maral Mut-component Yes wo , clesedsysm Yes No es = PrecessngV

  21. Slide 21: Ability of Handling Large Volumes with High Efficiencies

    Ability of Handling Large Volumes with High Efficiencies — Traditional processing methods may require 100 GMP units and 120+ FTE to process 200 units/day Traditional Technology ImmuneCyte Needs 2120 technians SEETEIE Traditional Technology ImmuneCyte TITTIRIRET esas < 10 technicians Superior Competi

  22. Slide 22: Significant Market Opportunity Exceeding $30B USD

    ain Significant Market Opportunity Exceeding $30B USD' — The historic comparison of cord blood banking vs. immune cell banking Fig 1. Groth of banked cord bloodunite since 1982 Festdemonatationot Fietcordbloedbanking = ‘iinicolusetuness ‘eniceesabianed ia i 1 t t ae 1988 1992 2016 A ee tl Fintsusces

  23. Slide 23: Cash Position; Investment Values and Peer Group Comparison

    Cash Position {in millions) $2.8 $22 $24 $2.2 $24 $2.0 $0.0 2018 Q3 2018 Q4 2019 a1 2019 Q2 2019.3 2019 a3 Pro Forma mCash on hand m™ Global distributor exclusivity fee 23 | Nasdaq:THMO Investment Values and Peer Group Comparison — With a strong cash position heading into 2020, ThermoGenesis is at i

  24. Slide 24: Experienced Leadership Team

    24 | Experienced Leadership Team Chris Xu, PhD, MBA, Chairman and Chief Executive Officer 20+ years in life sciences and pharmaceutical industry. Entrepreneur & investor, has invested in more than 20+ private and public companies. Invested close to $25 million into ThermoGenesis in the past three ye

  25. Slide 25: Board of Directors

    25 | Board of Directors io FO ND bo 25 | Nasdaq:THMO- Chris Xu, PhD, MBA | Chairman & CEO 20+ years in life sciences and pharmaceutical industry. Entrepreneur & investor, has invested in more than 20+ private and public companies. Invested close to $25 million into ThermoGenesis in the past three ye

  26. Slide 26: Pursuing Excellence for Cell Based Therapies

    Pursuing Excellence for Cell Based Therapies Cell Banking, Cell Process and Cell Therapy Company Contact: Investor Contact: For more information: ‘ThermoGenesis Holdings, Inc. Rx Communications For ThermoGenesis, visit: Wendy Samford Paula Schwartz www.thermogenesis.com 916-858-5191 917-322-2216 For

ThermoGenesis Holdings — Q3 2019 Earnings Presentation on 6ix